A Phase Ib Study of Sapacitabine and Olaparib in Patients with <i>BRCA1/2-</i> Mutated Metastatic Breast Cancer
Year: 2025
Type: article
Language: en
Topic: PARP inhibition in cancer therapy
Authors and affiliations:
raw_author_name: Filipa Lynce
raw_affiliation_strings: 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
2Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts
3Harvard Medical School, Boston, Massachusetts
Dana-Farber/Harvard Cancer Center, Boston, MA, United States
raw_author_name: Noah Graham
raw_affiliation_strings: 4Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
raw_author_name: Bose S. Kochupurakkal
raw_affiliation_strings: 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
2Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts
3Harvard Medical School, Boston, Massachusetts
Dana-Farber Cancer Institute & Harvard Medical School, Boston, MA, United States
raw_author_name: Huy Nguyen
raw_affiliation_strings: 5Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Boston, Massachusetts
6Broad Institute of MIT and Harvard, Cambridge, Massachusetts
Dana-Farber Cancer Institute, Boston, MA, United States
raw_author_name: Brittany Bychkovsky
raw_affiliation_strings: 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
2Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts
3Harvard Medical School, Boston, Massachusetts
Dana-Farber Cancer Institute, Boston, MA, United States
raw_author_name: Philip D. Poorvu
raw_affiliation_strings: 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
2Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts
3Harvard Medical School, Boston, Massachusetts
Dana-Farber Cancer Institute, Boston, United States
raw_author_name: Victoria Attaya
raw_affiliation_strings: 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
2Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
raw_author_name: Raechel Davis
raw_affiliation_strings: 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
2Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts
Dana-Farber Cancer Institute, Boston, MA, United States
raw_author_name: Molly DiLullo
raw_affiliation_strings: 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
2Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts
Dana-Farber Cancer Institute, United States
raw_author_name: Alan D. D’Andrea
raw_affiliation_strings: 3Harvard Medical School, Boston, Massachusetts
5Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Boston, Massachusetts
6Broad Institute of MIT and Harvard, Cambridge, Massachusetts
7Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
Dana-Farber Cancer Institute, Boston, MA, United States
raw_author_name: Judy E. Garber
raw_affiliation_strings: 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
2Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts
3Harvard Medical School, Boston, Massachusetts
8Division of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, Massachusetts
Dana-Farber Cancer Institute, Boston, MA, United States
raw_author_name: Kavita Garg
raw_affiliation_strings: 9Resolution Bioscience (now a part of Exact Sciences), Madison, Wisconsin
Resolution Bioscience, United States
raw_author_name: Lee P. Lim
raw_affiliation_strings: 9Resolution Bioscience (now a part of Exact Sciences), Madison, Wisconsin
Resolution Bioscience, United States
raw_author_name: Mark Li
raw_affiliation_strings: 9Resolution Bioscience (now a part of Exact Sciences), Madison, Wisconsin
Resolution Bioscience, United States
raw_author_name: Cloud P. Paweletz
raw_affiliation_strings: 10Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
raw_author_name: Nabihah Tayob
raw_affiliation_strings: 3Harvard Medical School, Boston, Massachusetts
4Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
raw_author_name: Geoffrey I. Shapiro
raw_affiliation_strings: 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
2Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts
3Harvard Medical School, Boston, Massachusetts
5Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Boston, Massachusetts
6Broad Institute of MIT and Harvard, Cambridge, Massachusetts
Dana-Farber Cancer Institute, Boston, MA, United States
raw_author_name: Sara M. Tolaney
raw_affiliation_strings: 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
2Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts
3Harvard Medical School, Boston, Massachusetts
Dana-Farber Cancer Institute, Boston, Massachusetts, United States